609 articles
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
Phase 3 trial pits lerodalcibep against inclisiran to determine which PCSK9 inhibitor best cuts LDL in cardiovascular high-risk patients.
A Phase 2 trial tests once-daily oral resmetirom (MGL-3196) against placebo to reduce LDL-C in patients with inherited high cholesterol.
A completed Phase 3 trial evaluates obicetrapib added to maximum lipid-lowering therapy in patients with familial hypercholesterolemia and ASCVD.
A Canadian pilot trial tests whether PT-guided fitness instructor classes improve daily function and balance in stroke survivors over 12 weeks.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A completed case-control study probes how early and lifetime trauma exposure shapes TMD severity and quality of life.
A completed RCT tested whether virtual reality could get seniors exercising more — and improve balance, gait, and independence.
A Columbia University trial tests whether a hip hop-based dementia education program builds lasting literacy and reduces stigma in children and families.
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
